A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 4, 2016

Study Completion Date

February 28, 2023

Conditions
Bladder Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.

Trial Locations (77)

10016

NYU Langone Medical Center, New York

10029

Mount Sinai School of Medicine - Tisch Cancer Institute, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

12200

Charité - Universitätsmedizin Berlin; CC 8: Chirurgische Medizin; Klinik für Urologie, Berlin

12208

New York Oncology Hematology, P.C., Albany

19107

Kimmel Cancer Center Thomas Jefferson University, Philadelphia

20057

Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.

20133

Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milan

20246

Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg

22031

Virginia Cancer Specialists, PC, Fairfax

23502

Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk

28007

Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid

28034

Hospital Ramon y Cajal; Servicio de Oncologia, Madrid

28041

Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid

30318

Piedmont Cancer Institute, PC, Atlanta

31008

Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona

32224

Mayo Clinic Cancer Center, Jacksonville

35294

University of Alabama At Birmingham, Birmingham

37203

Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville

40225

Universitätsklinikum Düsseldorf; Urologische Klinik, Düsseldorf

40402

Norton Cancer Institute, Louisville

41013

Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Seville

44106

Case Western Reserve Univ; Hem/Onc, Cleveland

44195

Cleveland Clinic, Cleveland

45242

Oncology Hematology Care Inc, Cincinnati

46526

Indiana University Health; Goshen Center for Cancer Care, Goshen

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Karmanos Cancer Institute, Detroit

52100

Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo

55404

Minnesota Oncology Minneapolis, Minneapolis

55905

Mayo Clinic - Rochester, Rochester

60426

Ingalls Memorial Hospital, Harvey

60637

University of Chicago; Hematology/Oncology, Chicago

68130

Urology Cancer Center & GU Research Network, Omaha

75475

APHP - Hospital Saint Louis, Paris

76104

Ctr for Cancer and Blood Disorders, Fort Worth

77024

Texas Oncology - Houston (Gessner), Houston

77030

Houston Methodist Hospital, Houston

78229

University of Texas Health Science Center at San Antonio, San Antonio

79106

Universitätsklinikum Freiburg; Chirurgische Klinik; Abteilung Urologie, Freiburg im Breisgau

80012

Rocky Mountain Cancer Center - Aurora, Aurora

80045

University Of Colorado, Aurora

81675

Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München

85258

Pinnacle Oncology Hematology, Scottsdale

85710

Arizona Oncology - HOPE Wilmot, Tucson

89128

Comprehensive Cancer Centers of Nevada, Las Vegas

90024

UCLA, Los Angeles

90025

The Angeles Clinic and Research Institute - W LA Office, Los Angeles

90033

USC Norris Cancer Center, Los Angeles

92069

Kaiser Permanente - San Marcos, San Marcos

92151

Hopital Foch; Oncologie, Suresnes

94589

Kaiser Permanente; Oncology Clinical Trials, Vallejo

94800

Institut Gustave Roussy; Oncologie Medicale, Villejuif

98109

Seattle Cancer Care Alliance, Seattle

94143-0106

UCSF, San Francisco

94305-5820

Stanford Cancer Center, Stanford

06030

University of Connecticut Health Center, Farmington

06520

Yale Cancer Center ; Medical Oncology, New Haven

02114

Massachusetts General Hospital;Oncology, Boston

02115

Dana Farber Cancer Inst. ; Dept. of Medical Oncology, Boston

02215

Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine, Boston

97401-8122

Willamette Valley Cancer Ctr - 520 Country Club, Eugene

V1Y 5L3

Bcca - Cancer Center Southern Interior, Kelowna

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

L1G 2B9

Lakeridge Health Oshawa; Oncology, Oshawa

K1H 8L6

The Ottawa Hospital Cancer Centre; Oncology, Ottawa

M4N 3M5

Sunnybrook Odette Cancer Centre, Toronto

M5G 2M9

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto

H3T 1E2

McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal

1066 CX

The Netherlands Cancer Institute - Antoni Van Leeuwenhoekziekenhuis, Amsterdam

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

08908

Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona

B15 2TH

University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital, Birmingham

EC1M 6BQ

Barts and The London, London

W1G 6AD

Sarah Cannon Research Institute, London

L63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Metropolitan Borough of Wirral

SM2 5PT

Royal Marsden Hospital; Dept of Medical Oncology, Sutton

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02951767 - A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | Biotech Hunter | Biotech Hunter